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Feasibility of Using Brain Attenuation Changes on CT 
to Accurately Predict Time of Ischaemic Stroke Onset
From the Division of Neuroimaging Sciences (GM, JW) and the Division of Clinical Neurosciences (PS), University of Edinburgh, UK
Grant Mair, Peter Sandercock, Joanna Wardlaw, IST-3 Collaborative Group.
Background
• Following ischaemic stroke, CT attenuation of affected 
brain reduces with time
• We piloted whether attenuation of infarct can be used 
to predict time of stroke onset
• This might enable the safe treatment of ischaemic 
strokes with intravenous alteplase for patients without 
a known time of symptom onset
Conclusions
• These results suggest it might be possible to predict time after stroke onset using only CT brain attenuation
• We have accurately classified patients as suitable or unsuitable for treatment with IV alteplase using this technique 
• We plan to validate these findings prospectively in a larger dataset and to test reader reliability
Reference: 1) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised-controlled trial. The Lancet 2012;379:2352-2363.
The University of Edinburgh is a charitable body, registered in Scotland, SC005336
Results
• We assessed 242 CT scans from 144 patients
• Among all scans, time ranged from 22 minutes to 268 hours
• There were no significant differences between development 
and test datasets (Table 1)
• The median percentage error for time estimation in the test 
dataset was 12.9% (positive value indicates under-estimation)
• Time estimation errors were greatest at extended time periods:
• 6.8% ≤ 4.5 hours from stroke onset
• 22.6% > 4.5 hours
• Estimation of patient suitability for treatment with IV alteplase:  
Sensitivity = 96%, Specificity = 87%, Accuracy = 96% (Fig 3)
Methods
We selected patients from the Third International Stroke Trial1 with thin-
slice (≤2.5 mm) CT brain imaging available at baseline (<6 hours from 
stroke onset) and follow-up who had cerebral infarct (but no haemorrhage) 
visible on their follow-up CT.
A wide range of stroke onset to scan times (time) were selected from 
among all available baseline and follow-up CT scans.
A neuroradiologist manually applied regions of interest (ROIs) within the 
infarct and an equivalent contralateral location (normal tissue) at each time 
point, guided by the infarct location on the follow-up scan (Fig 1). 
We derived infarct:normal tissue attenuation ratio .
Cases were assigned to development and testing datasets (75/25%) blind 
to attenuation ratio.
Attenuation ratio in the development dataset was plotted against time, a 
best-fit logarithmic function determined (Fig 2) and then used to estimate 
time in the test dataset.
We assessed accuracy of time estimates and tested the ability of this 
technique to correctly classify patients as suitable (≤4.5 hours from stroke 
onset) or unsuitable (>4.5 hours) for intravenous thrombolysis based on 
current European licensing for alteplase.Fig 1. ROI placement within infarct on baseline (left) and follow-up (right) thin-slice CT scans.
Fig 2. Best-fit logarithmic function for attenuation ratio versus time in the development dataset (n=180).
Table 1. Comparison of development and test datasets. Results are median (inter-quartile range) or %.
Variable Development Dataset (180) Test Dataset (62) P-value for Difference
Age (years) 83 (71-86) 81 (70-85) 0.451
Male Sex 43.7% 40% 0.640
NIHSS 15 (9-20) 15 (10-20) 0.826
Time from stroke onset to scan (hours) 15 (2.7-34.0) 16.7 (2.8-36.8) 0.806
Allocated to alteplase 49.2% 55% 0.463
Attenuation ratio 0.78 (0.56-0.88) 0.75 (0.55-0.88) 0.949
Fig 3. Estimated stroke onset to scan times in the test dataset (n=62), coloured to indicate if suitability for 
alteplase was correctly estimated. Upper figure highlights time estimates from 0-12 hours (>12 hours, all cases 
were correctly assessed as unsuitable for alteplase) and indicates 4.5 hour licensing limit for alteplase.  
Logarithmic function fit R2 = 0.754
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